Keyphrases
Glucagon-like
100%
Critically Ill Patients
100%
Glucose Metabolism
100%
Incretin
100%
Type 2 Diabetes Mellitus (T2DM)
60%
Severe Hypoglycemia
40%
Hyperglycemia
40%
Critical Illness
40%
Adverse Outcomes
40%
Insulin
40%
Blood Glucose
40%
Systemic Inflammation
20%
Neurological Death
20%
Neurological Sequelae
20%
Type 2 Diabetic Patients
20%
Glucagon
20%
Hypoglycemia
20%
High Risk
20%
Insulin Secretion
20%
Insulin Resistance
20%
Insulinotropic Effects
20%
Low Risk
20%
Cognitive Deficits
20%
Incretin Hormones
20%
New Drug Targets
20%
Organ Failure
20%
Healthy Individuals
20%
Nursing and Health Professions
Glucagon Like Peptide 1
100%
Incretin
100%
Hyperglycemia
60%
Glucose Blood Level
60%
Hypoglycemia
60%
Critical Illness
40%
Adverse Outcome
40%
Cognitive Defect
20%
Insulin Resistance
20%
Inflammation
20%
Patient with Type 2 Diabetes
20%
Glucagon
20%
Infusion
20%
Pharmacology, Toxicology and Pharmaceutical Science
Incretin
100%
Glucagon-Like Peptide-1
100%
Hypoglycemia
60%
Hyperglycemia
60%
Adverse Outcome
40%
Critical Illness
40%
Inflammation
20%
Glucagon
20%
Non Insulin Dependent Diabetes Mellitus
20%
Cognitive Defect
20%
Insulin Resistance
20%
Immunology and Microbiology
Incretin
100%
Glucose Metabolism
100%
Glucagon-Like Peptide-1
100%
Glucose Blood Level
60%
Insulin
40%
Insulin Resistance
20%
Insulin Release
20%
Systemic Inflammation
20%
Glucagon Release
20%